A Phase II Study of MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Patients With Newly Diagnosed Poor-risk or Relapsed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 31 May 2018
Price : $35 *
At a glance
- Drugs Inebilizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Apr 2018 Status changed from recruiting to discontinued as MEDI-551 removed from oncology by pharmaceutical company due to change in research target
- 22 Dec 2017 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 22 Sep 2017.